- Home
- AEMD vs SGRX Comparison
AEMD vs SGRX Comparison
Compare AEMD & SGRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AEMD | SGRX |
|---|---|---|
| Founded | 1984 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1M | 1.7M |
| IPO Year | 2008 | 2018 |
Fundamental Metrics
Financial Performance| Metric | AEMD | SGRX |
|---|---|---|
| Price | $6.43 | $1.79 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | ★ 3.6M | 210.3K |
| Earning Date | 02-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.51 | $1.40 |
| 52 Week High | $9.50 | $1.92 |
Technical Indicators
Market Signals| Indicator | AEMD | SGRX |
|---|---|---|
| Relative Strength Index (RSI) | 82.76 | 55.69 |
| Support Level | $2.08 | $1.40 |
| Resistance Level | N/A | $1.89 |
| Average True Range (ATR) | 0.42 | 0.25 |
| MACD | 0.44 | 0.01 |
| Stochastic Oscillator | 62.61 | 63.46 |
Price Performance
Historical ComparisonAbout AEMD Aethlon Medical Inc.
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.